Utility of Cerebrospinal Fluid Protein Levels as a Potential Predictive Biomarker of Disease Severity in HIV-Associated Cryptococcal Meningitis
Abstract Background Cerebrospinal fluid (CSF) protein levels exhibit high variability in HIV-associated cryptococcal meningitis from being normal to markedly elevated. However, the clinical implications of CSF protein levels in cryptococcal meningitis remain unclear.Methods We analysed data from 890 adults with HIV-associated cryptococcal meningitis randomized into two clinical trials in Uganda between 2015 and 2021. CSF protein was grouped into ≥100 mg/dL (n=249) and <100 mg/dL (n=641). We described baseline clinical variables and mortality by CSF protein levels.Results Approximately one-third of individuals had a baseline CSF protein ≥100 mg/dL. Those with CSF protein ≥100 mg/dL were more likely to present with Glasgow coma scale scores <15 (P<0.01), self-reported seizures at baseline (P=0.02), higher CD4 T-cells (p<0.001), and higher CSF white cells (p<0.001). Moreover, those with a baseline CSF protein ≥100 mg/dL also had a lower baseline CSF fungal burden (p<0.001) and a higher percentage of sterile CSF cultures at day 14 (p=0.02). Individuals with CSF protein ≥100 mg/dL demonstrated a more pronounced immune response consisting of upregulation of immune effector molecules pro-inflammatory cytokines, type-1 T-helper cell cytokines, type-3 chemokines, and immune-exhaustion marker (p<0.05). 18-week mortality risk in individuals with a CSF protein <100 mg/dL was 34% higher, (unadjusted Hazard Ratio 1.34; 95% CI, 1.05 to 1.70; p=0.02) than those with ≥100 mg/dL.Conclusion In cryptococcal meningitis, individuals with CSF protein ≥100 mg/dL more frequently presented with seizures, altered mental status, immune activation, and favourable fungal outcomes. Baseline CSF protein levels may serve as a surrogate marker of immune activation and prognosis..
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
bioRxiv.org - (2023) vom: 14. Dez. Zur Gesamtaufnahme - year:2023 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kasibante, John [VerfasserIn] |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| Themen: |
|---|
| doi: |
10.1101/2023.12.10.23299793 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI041848780 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI041848780 | ||
| 003 | DE-627 | ||
| 005 | 20231215091202.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231213s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2023.12.10.23299793 |2 doi | |
| 035 | |a (DE-627)XBI041848780 | ||
| 035 | |a (biorXiv)10.1101/2023.12.10.23299793 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kasibante, John |e verfasserin |0 (orcid)0000-0002-7252-4052 |4 aut | |
| 245 | 1 | 0 | |a Utility of Cerebrospinal Fluid Protein Levels as a Potential Predictive Biomarker of Disease Severity in HIV-Associated Cryptococcal Meningitis |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background Cerebrospinal fluid (CSF) protein levels exhibit high variability in HIV-associated cryptococcal meningitis from being normal to markedly elevated. However, the clinical implications of CSF protein levels in cryptococcal meningitis remain unclear.Methods We analysed data from 890 adults with HIV-associated cryptococcal meningitis randomized into two clinical trials in Uganda between 2015 and 2021. CSF protein was grouped into ≥100 mg/dL (n=249) and <100 mg/dL (n=641). We described baseline clinical variables and mortality by CSF protein levels.Results Approximately one-third of individuals had a baseline CSF protein ≥100 mg/dL. Those with CSF protein ≥100 mg/dL were more likely to present with Glasgow coma scale scores <15 (P<0.01), self-reported seizures at baseline (P=0.02), higher CD4 T-cells (p<0.001), and higher CSF white cells (p<0.001). Moreover, those with a baseline CSF protein ≥100 mg/dL also had a lower baseline CSF fungal burden (p<0.001) and a higher percentage of sterile CSF cultures at day 14 (p=0.02). Individuals with CSF protein ≥100 mg/dL demonstrated a more pronounced immune response consisting of upregulation of immune effector molecules pro-inflammatory cytokines, type-1 T-helper cell cytokines, type-3 chemokines, and immune-exhaustion marker (p<0.05). 18-week mortality risk in individuals with a CSF protein <100 mg/dL was 34% higher, (unadjusted Hazard Ratio 1.34; 95% CI, 1.05 to 1.70; p=0.02) than those with ≥100 mg/dL.Conclusion In cryptococcal meningitis, individuals with CSF protein ≥100 mg/dL more frequently presented with seizures, altered mental status, immune activation, and favourable fungal outcomes. Baseline CSF protein levels may serve as a surrogate marker of immune activation and prognosis. | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Irfanullah, Eesha |0 (orcid)0000-0001-7748-3598 |4 aut | |
| 700 | 1 | |a Wele, Abduljewad |4 aut | |
| 700 | 1 | |a Okafor, Elizabeth |0 (orcid)0000-0003-1495-4596 |4 aut | |
| 700 | 1 | |a Ssebambulidde, Kenneth |0 (orcid)0000-0002-8125-0698 |4 aut | |
| 700 | 1 | |a Okurut, Samuel |0 (orcid)0000-0002-9292-8687 |4 aut | |
| 700 | 1 | |a Kagimu, Enock |4 aut | |
| 700 | 1 | |a Gakuru, Jane |4 aut | |
| 700 | 1 | |a Rutakingirwa, Morris K. |4 aut | |
| 700 | 1 | |a Mugabi, Timothy |0 (orcid)0009-0006-8820-288X |4 aut | |
| 700 | 1 | |a Nuwagira, Edwin |0 (orcid)0000-0001-7526-9504 |4 aut | |
| 700 | 1 | |a Jjunju, Samuel |4 aut | |
| 700 | 1 | |a Mpoza, Edward |4 aut | |
| 700 | 1 | |a Tugume, Lillian |4 aut | |
| 700 | 1 | |a Nsangi, Laura |4 aut | |
| 700 | 1 | |a Musibire, Abdu K |4 aut | |
| 700 | 1 | |a Muzoora, Conrad |4 aut | |
| 700 | 1 | |a Rhein, Joshua |0 (orcid)0000-0002-0480-9646 |4 aut | |
| 700 | 1 | |a Meya, David B. |4 aut | |
| 700 | 1 | |a Boulware, David R. |4 aut | |
| 700 | 1 | |a Abassi, Mahsa |0 (orcid)0000-0001-9601-3006 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2023) vom: 14. Dez. |
| 773 | 1 | 8 | |g year:2023 |g day:14 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2023.12.10.23299793 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2023 |b 14 |c 12 | ||